Boone Capital Management LLC Purchases Shares of 167,932 LivaNova PLC $LIVN

Boone Capital Management LLC acquired a new stake in shares of LivaNova PLC (NASDAQ:LIVN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 167,932 shares of the company’s stock, valued at approximately $8,796,000. LivaNova comprises about 2.9% of Boone Capital Management LLC’s investment portfolio, making the stock its 13th largest position. Boone Capital Management LLC owned 0.31% of LivaNova as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the company. Artisan Partners Limited Partnership grew its holdings in shares of LivaNova by 94.5% in the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after purchasing an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after purchasing an additional 1,067,349 shares during the last quarter. Invesco Ltd. increased its position in shares of LivaNova by 714.7% during the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after purchasing an additional 902,447 shares during the last quarter. Scopia Capital Management LP bought a new position in LivaNova during the second quarter valued at $36,657,000. Finally, AQR Capital Management LLC lifted its holdings in shares of LivaNova by 30.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after acquiring an additional 478,525 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 1.4%

LivaNova stock opened at $58.46 on Friday. The business has a fifty day moving average price of $65.00 and a 200-day moving average price of $59.76. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $71.92. The stock has a market capitalization of $3.20 billion, a price-to-earnings ratio of -13.11 and a beta of 0.92. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.16.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. The company had revenue of $360.86 million during the quarter, compared to analysts’ expectations of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The firm’s revenue was up 12.2% compared to the same quarter last year. During the same period last year, the business posted $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities research analysts forecast that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on LIVN shares. KeyCorp initiated coverage on LivaNova in a report on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective for the company. Barclays upped their target price on LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Piper Sandler restated an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a report on Thursday, February 19th. Finally, Mizuho upped their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and a consensus price target of $74.78.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.